OBJECTIVES: Clinical outcomes in older adults with metastatic renal cell carcinoma (mRCC) are poorly understood, particularly in the era of targeted therapies. We characterize survival and relevant treatment-related variables in a modern series. MATERIALS AND METHODS: From an institutional database including 562 patients with RCC, a total of 219 patients with metastatic disease were identified for the current analysis. Survival was assessed in four age-based cohorts: (1) age<55, (2) age 55–64, (3) age 65–74, and(4) age≥75. The number of lines of therapy rendered was collected for each patient, and the reason for treatment discontinuation was characterized. RESULTS: Of the 219 patients assessed, median age was 58 (range, 26–87), and most patients had clear cell histology (82%) and prior nephrectomy (70.9%). The majority of patients were characterized as intermediate-risk (53%) by MSKCC criteria. Median survival in patients age≥75 was 12.5 months, as compared to 26.4 months for patients age<75 (P=0.003). Patients age≥75 received fewer lines of systemic therapy as compared to other age-based subsets, and more frequently discontinued therapies due to toxicity. CONCLUSIONS: Older adults represent a unique subpopulation of patients with mRCC, with distinct clinical outcomes. Further research is warranted to better understand the safety and tolerability of current therapies for mRCC in this group.
OBJECTIVES: Clinical outcomes in older adults with metastatic renal cell carcinoma (mRCC) are poorly understood, particularly in the era of targeted therapies. We characterize survival and relevant treatment-related variables in a modern series. MATERIALS AND METHODS: From an institutional database including 562 patients with RCC, a total of 219 patients with metastatic disease were identified for the current analysis. Survival was assessed in four age-based cohorts: (1) age<55, (2) age 55–64, (3) age 65–74, and(4) age≥75. The number of lines of therapy rendered was collected for each patient, and the reason for treatment discontinuation was characterized. RESULTS: Of the 219 patients assessed, median age was 58 (range, 26–87), and most patients had clear cell histology (82%) and prior nephrectomy (70.9%). The majority of patients were characterized as intermediate-risk (53%) by MSKCC criteria. Median survival in patients age≥75 was 12.5 months, as compared to 26.4 months for patients age<75 (P=0.003). Patients age≥75 received fewer lines of systemic therapy as compared to other age-based subsets, and more frequently discontinued therapies due to toxicity. CONCLUSIONS: Older adults represent a unique subpopulation of patients with mRCC, with distinct clinical outcomes. Further research is warranted to better understand the safety and tolerability of current therapies for mRCC in this group.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: A Karim Kader; Pheroze Tamboli; Tony Luongo; Surena F Matin; Kayla Bell; Eric Jonasch; David A Swanson; Christopher G Wood Journal: J Urol Date: 2007-03 Impact factor: 7.450
Authors: Michael D Gillett; John C Cheville; R Jeffrey Karnes; Christine M Lohse; Eugene D Kwon; Bradley C Leibovich; Horst Zincke; Michael L Blute Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Sharyn D Baker; Ron H N van Schaik; Laurent P Rivory; Albert J Ten Tije; Kimberly Dinh; Wilfried J Graveland; Paul W Schenk; Kellie A Charles; Stephen J Clarke; Michael A Carducci; William P McGuire; Fitzroy Dawkins; Hans Gelderblom; Jaap Verweij; Alex Sparreboom Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: T E Hutson; R M Bukowski; B I Rini; M E Gore; J M Larkin; R A Figlin; C H Barrios; B Escudier; X Lin; K Fly; B Martell; E Matczak; R J Motzer Journal: Br J Cancer Date: 2014-01-16 Impact factor: 7.640
Authors: Frede Donskov; Robert J Motzer; Eric Voog; Elizabeth Hovey; Carsten Grüllich; Louise M Nott; Katharine Cuff; Thierry Gil; Niels Viggo Jensen; Christine Chevreau; Sylvie Negrier; Reinhard Depenbusch; Lothar Bergmann; Izzy Cornelio; Anne Champsaur; Bernard Escudier; Sumanta Pal; Thomas Powles; Toni K Choueiri Journal: Eur J Cancer Date: 2019-12-27 Impact factor: 9.162